• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Medison to tough it out

Article

Since being forced into court receivership March 8, Korean ultrasound developer Medison had been seeking a white knight. But no more. The company best known for its pioneering efforts in 4D ultrasound has decided to stop looking for a corporate savior

Since being forced into court receivership March 8, Korean ultrasound developer Medison had been seeking a white knight. But no more. The company best known for its pioneering efforts in 4D ultrasound has decided to stop looking for a corporate savior and make it on its own. The company had attracted several suitors, including a number of foreign and domestic firms and a consortium. In each case, however, the proposed terms were too severe for Medison executives to accept, according to the company. In the meantime, the firm has divested itself of activities outside medical ultrasound and has posted strong sales revenue during this year's first half, leading to optimism that the company can succeed by itself.

Related Videos
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.